AleAnna (NASDAQ:ANNA – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
38.1% of AleAnna shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 42.9% of AleAnna shares are owned by insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for AleAnna and Xeris Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
| Xeris Biopharma | 1 | 2 | 5 | 0 | 2.50 |
Profitability
This table compares AleAnna and Xeris Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AleAnna | -46.01% | -14.90% | -8.74% |
| Xeris Biopharma | -5.88% | N/A | -4.66% |
Valuation and Earnings
This table compares AleAnna and Xeris Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AleAnna | $1.42 million | 133.77 | -$12.34 million | $0.04 | 71.25 |
| Xeris Biopharma | $203.07 million | 5.00 | -$54.84 million | ($0.10) | -61.20 |
AleAnna has higher earnings, but lower revenue than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Summary
Xeris Biopharma beats AleAnna on 8 of the 13 factors compared between the two stocks.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Receive News & Ratings for AleAnna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AleAnna and related companies with MarketBeat.com's FREE daily email newsletter.
